500 mg - pmda.go.jp
TRANSCRIPT
![Page 1: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/1.jpg)
500 mg
![Page 2: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/2.jpg)
O._._um_
![Page 3: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/3.jpg)
![Page 4: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/4.jpg)
4.
![Page 5: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/5.jpg)
:._3.5
:- HCI
:
N N| | - HCI
HNH
![Page 6: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/6.jpg)
1.5
ATP Adenosine triphosphate 3
AGI
BE
bid indie 1
BIG Biganide
CYP P450 P450
DDI Ding-drug
DPP4-I Dipeptidyl peptidase—4 DPP-4
EMA Agency
U.S. Food and
GLIN Glinide
GLP Good practice
GLPl-RA Glucagon-like peptide 1 receptor agonist GLPI
HbAlc HemoglobinAlc Alc
council for of El EUICH technical for pharmaceuticals
for human use
MMRM model repeated
OGTT Oral tolerance test E!
PD Phannacodynamic
PK
from the QTQT of the QRS to the end of
the T wave
QTc QT interval for heart rate QT
SGLTZ-I Sodium glucose 2 inhibitor SGLT2
SU Sulfonylurea
TZD Thiazolidinedione
![Page 7: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/7.jpg)
-‘-
![Page 8: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/8.jpg)
I
L
9'L
![Page 9: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/9.jpg)
1.5
20l-2c. 20.-20.
1.5-3
— -
s
5
5
5 3.1.4.04
5
5 3.1.4.06
5
5
5
5
5 3.1.4.11
5
5
s
![Page 10: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/10.jpg)
1.5
DDI
3.13.1.1
10
5
5
5
5
5
5
5
5 3.3.5.01
5
5
5
5
5
5
5 3.5.1.01
5
pH
![Page 11: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/11.jpg)
![Page 12: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/12.jpg)
![Page 13: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/13.jpg)
![Page 14: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/14.jpg)
![Page 15: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/15.jpg)
‘
![Page 16: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/16.jpg)
: 2 -
15
![Page 17: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/17.jpg)
![Page 18: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/18.jpg)
O._._u
![Page 19: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/19.jpg)
1.6
2021
2.SA
:2021 4 - <
![Page 20: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/20.jpg)
O._._um_
![Page 21: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/21.jpg)
mgmg mg mg mg
mg I mg3 mg
.:
-.
![Page 22: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/22.jpg)
_HHHH_HHI
![Page 23: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/23.jpg)
1.7
5 .
—
10mg25mg
lardiance Tablets 10mg-25mg
BoehringerIngelheim
I:
1 El
E l
I .
![Page 24: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/24.jpg)
![Page 25: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/25.jpg)
![Page 26: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/26.jpg)
![Page 27: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/27.jpg)
![Page 28: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/28.jpg)
![Page 29: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/29.jpg)
![Page 30: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/30.jpg)
1.7 11
![Page 31: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/31.jpg)
![Page 32: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/32.jpg)
1.7
* SGLTZ
‘J
E
‘
'J
-
—|
![Page 33: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/33.jpg)
![Page 34: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/34.jpg)
![Page 35: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/35.jpg)
![Page 36: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/36.jpg)
![Page 37: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/37.jpg)
![Page 38: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/38.jpg)
![Page 39: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/39.jpg)
![Page 40: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/40.jpg)
![Page 41: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/41.jpg)
![Page 42: 500 mg - pmda.go.jp](https://reader031.vdocuments.net/reader031/viewer/2022012508/61848776fd9fb24b64566d21/html5/thumbnails/42.jpg)
1.7 23
26.
MS